Erika Rich | Authors

March 31, 2022

A multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.

March 24, 2022

The importance of forming partnerships with patients and understanding their preferences for therapy when establishing treatment algorithms for patients with HER2-positive metastatic breast cancer.

March 17, 2022

Treatment recommendations for patients with HER2-positive metastatic breast cancer, like Erika Rich, upon identification of lesions in the brain.

March 10, 2022

Adverse events commonly associated with chemotherapies used to treat HER2-positive metastatic breast cancer, and recommendations to help equip patients with knowledge about what to expect during their treatment journey.

March 10, 2022

Erika Rich, a patient with HER2-positive metastatic breast cancer, explains why she opted to pursue a second opinion about her diagnosis and treatment options and proactively research her disease.

March 03, 2022

Julia A. LaBarbera, NP, reacts to the treatment approach used for a patient with HER2-positive metastatic breast cancer, and highlights the benefits of new subcutaneous injections of trastuzumab and pertuzumab that are available.

February 24, 2022

Radiation oncologist Kamran Ahmed, MD, comments on indications for using radiation therapy to treat patients with HER2-positive de novo metastatic breast cancer.

February 24, 2022

The rationale for treating Erika Rich, a patient with HER2-positive metastatic breast cancer, with docetaxel, trastuzumab, and pertuzumab.

February 17, 2022

Patient advocate Erika Rich compares initial symptoms that prompted her to seek a medical evaluation with symptoms commonly associated with HER2-positive metastatic breast cancer.

February 17, 2022

A discussion regarding treatment advances in HER2-positive metastatic breast cancer, a heterogeneous disease.